CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 238 enrolled
Drug / intervention
ABI using QuantaFlo™device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03161327
NCT03161327N/ACompleted

Positive Predictive Value of Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease: A Single Center, Prospective Clinical Trial

St. Louis University·interventional·Posted May 19, 2017·Updated Dec 11, 2018

In Brief

A clinical study evaluating ABI using QuantaFlo™ for Peripheral Artery Disease and 5 related conditions. Completed, enrolled 238 participants across 1 site.

Detailed Summary

Peripheral artery disease (PAD) affects 8-18 million in the US and is an economic burden, currently estimated to be greater than cancer and heart disease. Older age (\> 65 years), smoking, diabetes and kidney diseases are some risk factors associated with PAD and are known to have increased morbidity and mortality.Early detection is critical for mitigating PAD progression. Ankle-brachial index (ABI) testing is recommended by the US Preventative Services Task Force as an affordable and effective screening tool for evaluating PAD risk. QuantaFlo™ (Semler Scientific, Inc.) is a novel, noninvasive, 510K FDA approved digital device that is used as a screening tool to measure ABI of patients at risk of PAD. This single center prospective clinical trial will evaluate the sensitivity and specificity of digital ABI in detecting PAD using color Doppler ultrasound and 'gold standard' angiography as reference. Specifically in patient undergoing dialysis and who cannot undergo ABI using pressure cuffs dialysis grafts/ fistulae in the arms, we will evaluate the value of digital ABI in detecting PAD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 19, 2017
Enrollment StartJul 15, 2017
Primary CompletionSep 14, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.1 years ago

Interventions

ABI using QuantaFlo™device

Perform Digital ABI: * Will be performed by the nurse/medical assistant with training to perform this test * The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement. * The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes. * Usually each digit takes about 15 seconds to obtain a waveform * At the end of 60 seconds, an automated digital ABI will be generated. Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic. II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same.